Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).
Di Filippo F, Giacomini P, Rossi CR, Santinami M, Garinei R, Anzà M, Deraco M, Botti C, Perri P, Cavaliere F, Di Angelo P, Sofra C, Sperduti I, Pasqualoni R, Di Filippo S, Corrias F, Armenti A, Ferraresi V. Di Filippo F, et al. Among authors: ferraresi v. In Vivo. 2009 Mar-Apr;23(2):363-7. In Vivo. 2009. PMID: 19414428 Free article. Clinical Trial.
Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal women.
Milella M, Nisticò C, Ferraresi V, Vaccaro A, Fabi A, D'Ottavio AM, Botti C, Giannarelli D, Lopez M, Cortesi E, Foggi CM, Antimi M, Terzoli E, Cognetti F, Papaldo P. Milella M, et al. Among authors: ferraresi v. Breast Cancer Res Treat. 1999 Jun;55(3):259-66. doi: 10.1023/a:1006276120841. Breast Cancer Res Treat. 1999. PMID: 10517170 Clinical Trial.
Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion.
Di Filippo F, Giacomini P, Rossi CR, Santinami M, Anzà M, Garinei R, Perri P, Botti C, Di Angelo P, Sofra C, Pasqualoni R, Sperduti I, Cavaliere F, Di Filippo S, Corrias F, Armenti A, Ferraresi V, Ginebri A. Di Filippo F, et al. Among authors: ferraresi v. In Vivo. 2009 Mar-Apr;23(2):347-52. In Vivo. 2009. PMID: 19414425 Free article. Clinical Trial.
Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS.
Franzese O, Palermo B, Di Donna C, Sperduti I, Ferraresi V, Stabile H, Gismondi A, Santoni A, Nisticò P. Franzese O, et al. Among authors: ferraresi v. Oncoimmunology. 2016 Feb 1;5(5):e1114203. doi: 10.1080/2162402X.2015.1114203. eCollection 2016 May. Oncoimmunology. 2016. PMID: 27467927 Free PMC article.
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.
Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Braglia L, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Gronchi A, et al. Among authors: ferraresi v. J Clin Oncol. 2020 Jul 1;38(19):2178-2186. doi: 10.1200/JCO.19.03289. Epub 2020 May 18. J Clin Oncol. 2020. PMID: 32421444 Clinical Trial.
146 results